Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?

Citations Over TimeTop 10% of 2013 papers

Abstract

Iron plays a crucial role in a number of metabolic pathways including oxygen transport, DNA synthesis, and ATP generation. Although insufficient systemic iron can result in physical impairment, excess iron has also been implicated in a number of diseases including ischemic heart disease, diabetes, and cancer. Iron chelators are agents which bind iron and facilitate its excretion. Experimental iron chelators have demonstrated potent anti-neoplastic properties in a number of cancers in vitro. These agents have yet to be translated into clinical practice, however, largely due to the significant side effects encountered in pre-clinical models. A number of licensed chelators, however, are currently in clinical use for the treatment of iron overload associated with certain non-neoplastic diseases. Deferasirox is one such agent and the drug has shown significant anti-tumor effects in a number of in vitro and in vivo studies. Deferasirox is orally administered and has demonstrated a good side effect profile in clinical practice to date. It represents an attractive agent to take forward into clinical trials of iron chelators as anti-cancer agents.

Related Papers

• → Iron chelation adherence to deferoxamine and deferasirox in thalassemia(2011)73 cited
• → Comparison of Deferasirox (Exjade\(^®\)) and Deferoxamine (Desferal\(^®\)) Effects on Iron Overload in Patients with Blood Transfusion-Dependent \(\beta\)-Thalassemia Major in Iraq(2023)1 cited
• → Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis(2008)60 cited
• → COMPARISON OF DEFERASIROX AND DESFERRIOXAMINE AS IRON CHELATORS IN MULTI-TRANSFUSED PATIENTS OF Β-THALASSEMIA MAJOR(2023)1 cited
• → Adherence and Satisfaction of Deferasiroxversus Deferoxamine in Transfusion-Dependent Beta-Thalassemia(2020)